CRVS News and Press, Corvus Pharmaceuticals Inc. From 05/17/23

2023-05-17 12:56:05 ET Gainers: Immutep Limited ( IMMP ) +114% . WeTrade Group ( WETG ) +56% . Smart for Life ( SMFL ) +56% . National Western Life Group ( NWLI ) +40% . Bausch Health Companies ( BHC ) +37% . SelectQuote ( ...

2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...

BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML)...

2023-05-12 16:25:30 ET Summary Additional Phase 1b data for CPI-818 in T cell lymphoma is expected in this quarter. Phase 2 data for Ciforadenant is expected this year. The stock's upside momentum is expected to continue over the next 1 year due to above catalysts. Corvu...

2023-05-10 12:34:48 ET Gainers: Unique Fabricating ( UFAB ) +132% . Harbor Custom Development HCDI +130% . CTI BioPharma CTIC +85% . Corvus Pharmaceuticals ( CRVS ) +57% . Microvast Holdings MVST +58% . Benson Hill BHIL +42% . Mi...

2023-05-08 22:24:08 ET Corvus Pharmaceuticals, Inc. (CRVS) Q1 2023 Earnings Conference Call May 08, 2023, 04:30 PM ET Company Participants Zack Kubow - IR-Real Chemistry Leiv Lea - CFO Richard Miller - CEO James Rosenbaum - SVP-Research Conference Call ...

2023-05-08 16:28:06 ET Corvus Pharmaceuticals press release ( NASDAQ: CRVS ): Q1 GAAP EPS of -$0.17 misses by $0.01 . For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.17 misses by $0.01

Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals...

BURLINGAME, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on May 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and repor...

Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased T cell cytolytic capacity and reduction of T cell exhaustion Enrollment continu...